Antiparkinsonian therapy modifications in PD patients after STN DBS: A retrospective observational analysis

Parkinsonism and Related Disorders

Volumn 14, Issue 8, 2008, Pages 608-612

  Zibetti, M ^a   Pesare, M ^a   Cinquepalmi, A ^a   Rosso, M ^a   Bergamasco, B ^a,b   Ducati, A ^a   Lanotte, M ^a   Lopiano, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS   (Italy)

Author keywords

Antiparkinsonian treatment; Deep Brain Stimulation; Dopamine agonists; Levodopa; Parkinson's disease; Subthalamic Nucleus

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BIPERIDEN; BORNAPRINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; ORPHENADRINE; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CONFUSION; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSARTHRIA; EYELID OPENING APRAXIA; FEMALE; FOLLOW UP; HUMAN; HYPOMANIA; HYPOPHONIC DYSARTHRIA; IATROGENIC DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHARMACEUTICAL CARE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUBTHALAMIC NUCLEUS; TIME FACTORS;

EID: 55749089557     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.12.009     Document Type: Article

References (18)

1. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., et al. Five years follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 (2003) 1925-1934
2. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355 (2006) 896-908
3. Rodriguez-Oroz M.C., Obeso J.A., Lang A.E., Houeto J.L., Pollak P., Rehncrona S., et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128 (2005) 2240-2249
4. Krack P., Fraix V., Mendes A., Benabid A.L., and Pollak P. Post-operative management of subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 17 Suppl. 3 (2002) S188-S197
5. Kleiner-Fisman G., Herzog J., Fisman D.N., Tamma F., Lyons K.E., Pahwa R., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl. 14 (2006) S290-S304
6. Ostergaard K., Sunde N., and Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 17 (2002) 693-700
7. Valldeoriola F., Pilleri M., Tolosa E., Molinuevo J.L., Rumia J., and Ferrer E. Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long term follow-up of patients. Mov Disord 17 (2002) 125-132
8. Thobois S., Corvaisier S., Mertens P., Di Guardo C., Mollion H., Guenot M., et al. The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation. Eur Neurol 49 (2003) 59-63
9. Fraix V., Houeto J.L., Lagrange C., Le Pen C., Krystkowiak P., Guehl D., et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 77 (2006) 443-449
10. Lanotte M.M., Rizzone M., Bergamasco B., Faccani G., Melcarne A., and Lopiano L. Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation. J Neurol Neurosurg Psychiatry 72 (2002) 53-58
11. Defer G.L., Widner H., Marie R.M., Remy P., and Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14 (1999) 572-584
12. Reichmann H., Herting B., Miller A., and Sommer U. Switching and combining dopamine agonists. J Neural Transm 110 (2003) 1393-1400
13. Hilker R., Portman A.T., Voges J., Staal M.J., Burghaus L., van Laar T., et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76 (2005) 1217-1221
14. Ostergaard K., and Aa Sunde N. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 21 (2006) 624-631
15. Lemke M.R., Brecht H.M., Koester J., and Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 248 (2006) 266-270
16. Barone P., Scarzella L., Marconi R., Antonini A., Morgante L., Bracco F., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 253 (2006) 601-607
17. Temel Y., Kessels A., Tan S., Topdag A., Boon P., and Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson's disease: a systematic review. Parkinsonian Relat Disord 12 (2006) 265-272
18. Pogarell O., Gasser T., van Hilten J.J., Spieker S., Pollentier S., Meier D., et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72 (2002) 713-720